Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 0.75 |
| ▸ | MAPK12 | P53778 | 16/20 | 0.75 |
| ▸ | HCK | P08631 | 14/20 | 0.75 |
| ▸ | TNF | P01375 | 1/20 | 0.63 |
| ▸ | SRC | P12931 | 2/20 | 0.62 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.60 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.60 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31086867 | 0.87 | MAPK14 (0.86) | MAPK14MAPK12HCKTNFSRC | |
| SCHEMBL2405604 | 0.87 | MAPK14 (0.86) | MAPK14MAPK12HCKTNFSRC | |
| SCHEMBL2581629 | 0.87 | MAPK14 (0.68) | MAPK14MAPK12HCKTNFSRC | |
| SCHEMBL2526365 | 0.86 | MAPK14 (0.74) | MAPK14MAPK12HCKTNFSRC | |
| SCHEMBL2408004 | 0.86 | MAPK14 (1.00) | MAPK14MAPK12HCKTNFSRC | |
| SCHEMBL14687978 | 0.86 | MAPK14 (0.81) | MAPK14MAPK12HCKSRC | |
| SCHEMBL2404321 | 0.85 | MAPK14 (0.82) | MAPK14MAPK12HCKTNFSRC | |
| SCHEMBL2576702 | 0.85 | MAPK14 (0.67) | MAPK14MAPK12HCKTNFSRC | |
| SCHEMBL2533684 | 0.84 | MAPK14 (0.78) | MAPK14MAPK12HCKTNFSRC | |
| SCHEMBL13563524 | 0.84 | MAPK14 (0.78) | MAPK14MAPK12HCKTNFSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2556068-B1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2019-01-23 | — | — | EP | disclosed |
| US-9024041-B2 | P38 MAP kinase inhibitors | RESPIVERT LTD. (GB) | 2015-05-05 | — | — | US | disclosed |
| US-20130040962-A1 | P38 MAP Kinase Inhibitors | RESPIVERT LTD (GB) | 2013-02-14 | — | — | US | disclosed |
| EP-2556068-A1 | P38 MAP KINASE INHIBITORS | Respivert Limited (GB) | 2013-02-13 | — | — | EP | disclosed |
| WO-2011124930-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2011-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040962-A1 | P38 MAP Kinase Inhibitors | MAPK15, MAPK1, MAP3K15 | MAPK14 4/4885MAPK12 21/4885HCK 1445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.